Skip to main content
S&P 5007,743.98+0.28%DOW52,475.10+0.19%NASDAQ26,549.85+0.27%BTC$81,213.00+0.54%ETH$2,358.51+0.51%GOLD$4,066.90+0.38%OIL$101.96-0.80%
Smart Investors Daily
SID Premium
KN

NASDAQ · KNSA

Kiniksa Pharmaceuticals, Ltd.

Healthcare · Biotechnology

$89.20

Up+$5.98 (+6.70%)

Updated Oct 28, 2026, 8:03 PM

SID Score

5.8/10

Composite research score

Smart Money

62/100

Neutral

Market cap
3B
P/E ratio
83.96
Dividend yield
0.00%
52-week range
$35.20 – $90.80
Volume
2.32M
Avg. volume
427.35K

Price performance · KNSA

KNSA price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Oct 27, 2026

KNSA closed at $89.20 after 21 trading sessions, up 17.79% for the selected period.

Last close
$89.20
Period change
+17.79%
Period low
$72.98
Period high
$89.20
Daily close
View OHLC price history
KNSA OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 27, 2026$85.00$90.80$82.26$89.202.32M
Oct 26, 2026$75.995$76.48$70.67$72.981.43M
Oct 23, 2026$80.16$80.22$76.58$76.73576.56K
Oct 22, 2026$79.32$81.30$78.3892$80.79429.71K
Oct 21, 2026$83.41$84.06$78.74$79.70838.63K
Oct 20, 2026$80.25$83.78$79.88$83.171.24M
Oct 19, 2026$78.78$80.61$78.3601$79.48602.15K
Oct 16, 2026$79.94$80.34$76.88$78.59525.19K
Oct 15, 2026$79.85$82.979$79.62$79.941.49M
Oct 14, 2026$78.115$79.96$77.70$78.84576.56K
Oct 13, 2026$79.21$80.00$78.45$78.53578.48K
Oct 12, 2026$80.00$80.9899$78.82$79.24340.94K
Oct 9, 2026$78.24$80.50$78.03$79.78430.28K
Oct 8, 2026$77.18$78.83$75.44$78.75411.57K
Oct 7, 2026$76.18$79.22$74.70$77.96381.05K
Oct 6, 2026$76.00$77.32$73.84$77.09378.74K
Oct 5, 2026$75.97$76.79$75.285$76.31391.51K
Oct 2, 2026$75.58$76.22$74.5601$75.79376.31K
Oct 1, 2026$73.87$76.11$73.14$75.22878.56K
Sep 30, 2026$76.55$76.55$73.76$74.61650.61K
Sep 29, 2026$75.32$76.52$74.33$75.73620.7K

Latest KNSA news

The latest Smart Investors Daily articles mentioning KNSA.

Stock researchCompany · Overview

KNSA research

Overview

Company profile and research snapshot.

Company profile

Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$51.00
Implied upside
—
Analysts
—
KNSA recent ratings
DateFirmRatingTarget
Jul 30, 2026Goldman SachsBuy—
Jul 29, 2026CitigroupBuy—
Jul 29, 2026WedbushOutperform—
Jul 29, 2026Canaccord GenuityBuy—
Jul 29, 2026JP MorganOverweight—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 24, 2026

3 Healthcare Stocks To Watch In October 2026

Americans now have a record share of their financial assets in equities, which raises the stakes for choosing where every new dollar goes. With so much capital already tied to markets, investors are paying closer attention to sectors that can offer essential services through different economic moods. Healthcare fits that bill. This article breaks down three leading healthcare stocks from a curated screener that focuses on financial strength and staying power. The stocks highlighted below are...

Yahoo · Oct 22, 2026

Kiniksa Pharmaceuticals to Report Third Quarter 2026 Financial Results on October 27, 2026

LONDON, Oct. 22, 2026 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, October 27, 2026 at 8:30 a.m. Eastern Time to report its third quarter 2026 financial results and recent portfolio execution. A live webcast will be accessible through the Investors & Media section of the company’s website at www.kiniksa.com. Individuals interested in participating in the call via telephone may regist

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By